Phenylephrine liquid formulations

1. An aqueous oral pharmaceutical composition comprising:

a). 0.05% w/v phenylephrine;

b). 0.2% w/v sucralose;

c). 25% w/v glycerin;

d). 10% w/v sorbitol wherein the glycerin to sorbitol ratio is 2.5 to 1; and

e.) wherein the composition is substantially free of phenylephrine degradants as measured under conditions of 60° C. and 60% relative humidity for approximately three weeks.

2. The composition of claim 1 , further comprising a flavor system.

3. The composition of claim 2 , wherein the flavor system includes non-aldehyde flavorants.

4. The composition of claim 1 , further comprising at least one second active agent selected from the group consisting of analgesics, decongestants, expectorants, antitussives, antipyretics, anti-inflammatory agents, cough suppressants and antihistamines.

5. The composition of claim 4 , wherein the second active agent is selected from the group consisting of non-steroidal anti-inflammatory drugs (NSAIDS), propionic acid derivatives, ibuprofen, naproxen, ketoprofen, flurbiprofen, fenoprofen, suprofen, fluprofen, fenbufen; acetic acid derivatives, tolmetin sodium, zomepirac, sulindac, indomethacin, fenamic acid derivatives, mefenamic acid meclofenamate sodium, biphenyl carboxylic acid derivatives, diflunisal, flufenisal, oxicams, piroxicam, sudoxicam, isoxicam, chlorpheniramine, brompheniramine; dexchlorpheniramine, dexbrompheniramine, triprolidine, chlorcyclizine, diphenhydramine, doxylamine, tripelenamine, cyproheptatine, bromodiphenhydramine, phenindamine, pyrilamine, azatadine, acrivastine, astemizole, azelastine, cetirizine, ebastine, fexofenadine, ketotifen, carbinoxamine, desloratadine, loratadine, pheniramine, thonzylamine, mizolastine, terfenadine, chlophendianol, caramiphen, dextromethorphan, diphenhydramine, codeine, hydrocodone, pseudoephedrine, ephedrine, phenylephrine, phenylpropenolamine, terpin hydrate, guaifenesin, potassium, potassium guaicolsulfonate, Cox 2 inhibitors, Celecoxib, Rofecoxib, Valdecoxib, aspirin, acetaminophen, phenacetin, salicylate salts and combination thereof.

6. The composition of claim 4 , wherein the at least one second active agent is selected from the group consisting of chlorpheniramine, dextromethorphan, guaifenesin, acetaminophen, chlophendianol, diphenhydramine, brompheniramine, loratadine, aspirin and doxylamine succinate.

7. The composition of claim 1 , further comprising a buffering agent.

8. The composition of claim 7 , wherein the buffering agent maintains a pH below about 5.4 in the composition.

9. The composition of claim 7 , wherein the buffering agent maintains a pH between about 2 and about 4.5 in the composition.

10. The composition of claim 1 , further comprising a preservative.

11. The composition of claim 10 , wherein the preservative is selected from the group consisting of sodium benzoate, sorbates, parabens, EDTA and combinations thereof.

12. The composition of claim 1 , further comprising an antioxidant.

13. The composition of claim 12 , wherein the antioxidant is propyl gallate.

14. An aqueous pharmaceutical solution comprising:

a). 0.05% w/v phenylephrine;

b). 0.2% w/v sucralose;

c). 25% w/v glycerin;

d). 10% w/v sorbitol, wherein the glycerin to sorbitol ratio is 2.5:1;

e.) 0.02% w/v brompheniramine; and

f.) wherein the composition is substantially free of phenylephrine degradants as measured under conditions of 60° C. and 60% relative humidity for approximately three weeks.

15. The solution of claim 14 , further comprising up to about 1.25% w/v citric acid.

16. The solution of claim 14 , further comprising up to about 0.2% w/v propyl gallate.

17. An aqueous oral pharmaceutical suspension composition comprising:

a). 0.05% w/v phenylephrine,

b). 0.2% w/v sucralose,

c) a viscosity modifying agent,

d). 25% w/v glycerin,

e). 10% w/v sorbitol wherein the glycerin to sorbitol ratio is 2.5:1; and

f.) wherein the composition is substantially free of phenylephrine degradants as measured under conditions of 60° C. and 60% relative humidity for approximately three weeks.

18. The suspension of claim 17 , wherein the viscosity modifying agent is selected from the group consisting of chitosen, microcrystalline cellulose, xanthan, HPMC, HPC, HEC, galaotomannons and combinations thereof.

19. The suspension of claim 17 , further comprising an effective amount of at least a second active agent selected from the group consisting of analgesics, decongestants, expectorants, anti-tussives, antipyretics, anti-inflammatory agents, cough suppressants and antihistamines.

20. The suspension of claim 19 , wherein the second active agent is selected from the group consisting of non-steroidal anti-inflammatory drugs (NSAIDS), propionic acid derivatives, ibuprofen, naproxen, ketoprofen, flurbiprofen, fenoprofen, suprofen, fluprofen, fenbufen; acetic acid derivatives, tolmetin sodium, zomepirac, sulindac, indomethacin, fenamic acid derivatives, mefenamic acid meclofenamate sodium, biphenyl carboxylic acid derivatives, diflunisal, f1ufenisal, oxicams, piroxicam, sudoxicam, isoxicam, chlorpheniramine, brompheniramine; dexchlorpheniramine, dexbrompheniramine, triprolidine, chlorcyclizine, diphenhydramine, doxylamine, tripelenamine, cyproheptatine, bromodiphenhydramine, phenindamine, pyrilamine, azatadine, acrivastine, astemizole, azelastine, cetirizine, ebastine, fexofenadine, ketotifen, carbinoxamine, desloratadine, loratadine, pheniramine, thonzylamine, mizolastine, terfenadine, chlophendianol, caramiphen, dextromethorphan, diphenhydramine, codeine, hydrocodone, pseudoephedrine, ephedrine, phenylephrine, phenylpropenolamine, terpin hydrate, guaifenesin, potassium, potassium guaicolsulfonate, Cox 2 inhibitors, Celecoxib, Rofecoxib, Valdecoxib, aspirin, acetaminophen, phenacetin, salicylate salts and combination thereof.

21. The suspension of claim 20 , wherein the second active agent is selected from the group consisting of chlorpheniramine, dextromethorphan, guaifenesin, acetaminophen, chlorphendianol, doxylamine succinate and ibuprofen.